Key result
Transdermal hormone replacement therapy for 6 months reduced plasma viscosity (-18% vs -14%) and thromboxane B2 (-93% vs -88%) in non-smokers and heavy smokers, with less benefit in smokers.
Why the study?
Does transdermal hormone replacement therapy improve plasma viscosity, thromboxane B2 levels, and vascular impedance in postmenopausal non-smokers and heavy smokers?
Cohort (n=43)
Does transdermal hormone replacement therapy improve plasma viscosity, thromboxane B2 levels, and vascular impedance in postmenopausal non-smokers and heavy smokers?
Transdermal hormone replacement therapy improves cardiovascular risk markers such as plasma viscosity and vascular impedance in postmenopausal women, but these benefits are significantly blunted in heavy smokers.
Transdermal HRT was associated with improved markers, blunted in smokers; leaves open effects on events and requires RCT confirmation.
OBJECTIVES: To evaluate the effects of transdermal hormone replacement therapy (HRT) on some biological cardiovascular risk factors, specifically thromboxane B2 level and plasma viscosity. Furthermore, we investigated Doppler flow modifications at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries, and evaluated whether there were significant differences, in the examined parameters, between postmenopausal women who were non-smokers and heavy smokers. METHODS: Forty-three postmenopausal women (age 53.6 +/- 3.3 years, mean +/- standard deviation) participated in the study and were divided into two groups (Group I: n = 21, normal controls; and Group II: n = 22, heavy smokers). Patients were treated with continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). RESULTS: Results showed a beneficial effect of hormone substitution after 6 months of therapy. Plasma viscosity decreased significantly after 6 months of therapy both in non-smokers and heavy smokers (-18% and -14%, respectively). Plasma levels of thromboxane B2, which were similar at baseline, underwent a dramatic reduction in both Group I and Group II (-93% and -88%, respectively). Doppler assessment of pulsatility index at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries showed a significant reduction in vascular impedance at the end of treatment in both groups. However, the treatment was significantly less beneficial, in terms of the analyzed factors, in heavy smokers. CONCLUSIONS: Cigarette smoking represents a cardiovascular risk factor that can only partially be modified by the administration of transdermal HRT.
No takes yet. Share an insight, caveat, or question.
Mancini et al. (2005) conducted a cohort in Postmenopausal women (n=43). Transdermal hormone replacement therapy vs. Baseline was evaluated on Plasma viscosity and thromboxane B2 levels. Transdermal hormone replacement therapy for 6 months reduced plasma viscosity (-18% vs -14%) and thromboxane B2 (-93% vs -88%) in non-smokers and heavy smokers, with less benefit in smokers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: